PPP1R14A
Reactivité: Humain, Souris, Rat
WB, ELISA, IHC
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
Western Blot: 1/500 - 1/1000. Immunohistochemistry: 1/50 - 1/200. Immunofluorescence: 1/50 - 1/200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
CPI-17 is a phosphorylation-dependent inhibitory protein for smooth muscle myosin phosphate. CPI-17 was originally identified as a 17 kDa PKC-potentiated inhibitory protein of protein phosphatase-1, which is dominantly expressed in smooth muscle. Phosphorylation at Threonine 38, in vitro, by PKC or Rho-kinase enhances the inhibitory potency toward myosin phosphatase. CPI-17 is also phosphorylated at Threonine 38 by protein kinase N and might be involved in the calcium sensitization of smooth muscle contraction as a downstream effector of Rho and/or arachidonic acid. CPI-17 is dually phosphorylated at Serine 12 and Threonine 38 by a MYPT-associated kinase, M110 kinase.Synonyms: 17 kDa PKC-potentiated inhibitory protein of PP1, CPI-17, CPI17, PPP1INL, Protein phosphatase 1 regulatory subunit 14A